BioDelivery Sciences Shares Tick Higher As Interim FY21 Sales Beat Expectations


BioDelivery Sciences International Inc BDSI expects FY21 total revenues of $165-$167 million, compared to previous guidance of $162-$167 million and the consensus of $$165.34 million.

  • Belbuca (buprenorphine buccal film) FY21 sales are expected to be $147-$148 million, compared to prior guidance of $144-$148 million.
  • During Q4 FY21, Belbuca achieved a total prescription (TRx) market share of 5.0%, a record for BDSI, and volumes were at an all-time high of 122,000 TRx. 
  • For FY21, Belbuca TRx volumes were up 8.8% Y/Y despite headwinds. 
  • Symproic (naldemedine) similarly achieved an all-time high 13.0% TRx share and volumes of 19,000 for Q4 2021, an increase of 5.3% Y/Y.
  • EBITDA for the full-year 2021 is expected to be $40 - $45 million range, including the Company's pre-launch investment for Elyxyb, compared with previous guidance of over $40 million.
  • Price Action: BDSI shares are up 7.83% at $3.24 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: EarningsLong IdeasNewsPenny StocksGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!